SCAI along with other members of the Alliance of Specialty Medicine expressed concerns to CMS regarding the proposal to expand step-therapy to Part B drugs. Concerns expressed were regarding administrative burdens and interference with physician’s treatment plans. The Alliance is calling for CMS to rescind the 2018 memo as it provides more guidance and contains few binding requirements for insurers to ensure patients are not harmed. SCAI will continue to work with the Alliance on this important issue. To learn more.